RA Capital Healthcare Fund LP 4

What Happened RA Capital Management, L.P. (a reporting 10% owner via affiliated funds) sold a total of 416,911 shares of Werewolf Therapeutics (HOWL) on June 17, 2026. The filing shows two disposal entries: 389,216 shares for $136,226 and 27,695 shares for $9,693, a combined proceeds total of $145,919. The reported weighted-average price was $0.35 per share (sales occurred at prices ranging $0.34–$0.39). These were sales (not purchases), which are often routine fund or liquidity transactions rather than a direct management signal.

Key Details

• Transaction date: June 17, 2026; Filing date: June 22, 2026 (filed 5 days after the trades).
• Reported price: weighted average $0.35; per-footnote range $0.34–$0.39 across multiple trades.
• Shares sold: 416,911 total (389,216 + 27,695); total proceeds ≈ $145,919.
• Shares owned after transaction: not specified in the public Form 4 provided.
• Footnotes: F1 notes weighted-average price and offers to provide breakdown by price; F2/F4 indicate holdings were held directly by RA Capital Healthcare Fund, L.P. and Nexus Fund II; F3 explains the adviser/fund structure and disclaimers of beneficial ownership.
• Transaction type: marked as "S" (sale) — open market or private sale.

Context This filing reflects activity by an institutional 10% owner (funds managed by RA Capital), not an individual officer or director. Institutional sales can reflect portfolio rebalancing, liquidity needs, or other fund-level decisions and do not necessarily indicate insider views on company prospects. No option exercises, awards, gifts, or 10b5-1 plans are disclosed in this filing.